Watson Pharmaceuticals wins groundbreaking FDA case
This article was originally published in Clinica
Executive Summary
In a landmark decision with potential implications for devices and diagnostics manufacturers, Watson Pharmaceuticals has been found not to have breached copyright in labelling for a product after the FDA demanded that it follow the wording already permitted for an earlier approved product.